Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

Rhea-AI Summary

Palvella Therapeutics (Nasdaq: PVLA) closed an upsized public offering on February 27, 2026, selling 1,840,000 common shares including full exercise of a 240,000-share underwriter option at $125.00 per share, generating $230.0 million in gross proceeds.

Palvella said it will use net proceeds to advance development of QTORIN rapamycin and QTORIN pitavastatin, support R&D, and for working capital and general corporate purposes. The shares were offered under a Form S-3 shelf registration declared effective January 29, 2026.

Positive

• $230.0 million gross proceeds raised from the offering
• Full exercise of underwriters' option: 240,000 additional shares sold
• Proceeds earmarked to fund development of QTORIN rapamycin and QTORIN pitavastatin

Negative

• Issuance of 1,840,000 new shares may dilute existing shareholders
• Gross proceeds of $230.0 million exclude underwriting discounts, commissions, and offering expenses

News Market Reaction – PVLA

-1.78%

1 alert

-1.78% News Effect

-$34M Valuation Impact

$1.90B Market Cap

0.1x Rel. Volume

On the day this news was published, PVLA declined 1.78%, reflecting a mild negative market reaction. This price movement removed approximately $34M from the company's valuation, bringing the market cap to $1.90B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Shares offered: 1,840,000 shares Underwriters’ option shares: 240,000 shares Offering price: $125.00 per share +1 more

4 metrics

Shares offered 1,840,000 shares Total common stock in the upsized public offering, including option exercise

Underwriters’ option shares 240,000 shares Additional shares from full exercise of underwriters’ option

Offering price $125.00 per share Public offering price for the common stock

Gross proceeds $230.0 million Aggregate gross proceeds before fees and expenses

Market Reality Check

Price: $132.61 Vol: Volume 654,366 is 1.48x t...

normal vol

$132.61 Last Close

Volume Volume 654,366 is 1.48x the 20-day average of 441,788, indicating elevated trading interest around the offering close. normal

Technical Shares trade well above the 200-day MA (63.47) at 135.02, while sitting 10.69% below the 52-week high of 151.18.

Peers on Argus

PVLA fell 8.98% while the momentum scanner shows only one peer (SVRA) in focus, ...

1 Down

PVLA fell 8.98% while the momentum scanner shows only one peer (SVRA) in focus, moving -9.14%. Broader peers show mixed single-day moves, pointing to a stock-specific reaction rather than a coordinated biotech sector swing.

Previous Offering Reports

2 past events · Latest: Feb 25 (Negative)

Same Type Pattern 2 events

Date	Event	Sentiment	Move	Catalyst
Feb 25	Offering pricing	Negative	+6.8%	Priced upsized equity offering at $125 with underwriter option and ~$200M proceeds.
Feb 24	Offering proposed	Negative	+6.8%	Proposed $150M equity raise plus additional underwriter option for common stock.

Pattern Detected

Recent equity offering announcements have been followed by positive price moves of about 6.8%, so today’s negative reaction to the closing contrasts with earlier optimism around the same financing.

Recent Company History

Over the past weeks, Palvella has advanced both clinical and financing milestones. On Feb 24–25, 2026, it announced and priced an upsized equity offering at $125.00 per share, with gross proceeds around $200 million. Those financing headlines were followed by gains of about 6.8%. Today’s news confirms the final closing and expanded size of that deal, building on the same capital-raising sequence that followed strong Phase 3 SELVA data for QTORIN rapamycin.

Historical Comparison

+6.8% avg move · Past offering headlines for PVLA saw average moves of about +6.8%. Today’s offering-close news contr...

offering

+6.8%

Average Historical Move offering

Past offering headlines for PVLA saw average moves of about +6.8%. Today’s offering-close news contrasts with that pattern, as shares declined 8.98%, marking a notable deviation.

Financing has progressed from a proposed equity raise to pricing and now closing of the same upsized common stock offering.

Market Pulse Summary

This announcement confirms the closing of an upsized equity raise, adding 1,840,000 shares at $125.0...

Analysis

This announcement confirms the closing of an upsized equity raise, adding 1,840,000 shares at $125.00 for gross proceeds of $230.0 million. Recent history shows a sequence from proposed to priced to closed financing, following strong Phase 3 data for QTORIN rapamycin. Investors may focus on how efficiently these funds support development of QTORIN rapamycin and QTORIN pitavastatin, alongside monitoring upcoming regulatory milestones and further clinical disclosures.

Key Terms

public offering, underwriters’ option, prospectus supplement, u.s. food and drug administration (fda)

4 terms

public offering financial

"announced that it closed its previously announced upsized public offering on February 27, 2026."

A public offering is when a company sells shares to the general public through the stock market, either by issuing new shares to raise cash or by letting existing owners sell their stakes. Think of it like a business opening its doors to many new owners at once: it can bring in money for growth but also increases the number of shares available, which can change the stock price and dilute existing ownership — key factors investors watch closely.

underwriters’ option financial

"which included the exercise in full of the underwriters’ option to purchase 240,000 additional shares"

An underwriters’ option is a provision in a securities offering that lets the group selling the new shares buy a fixed extra amount (often up to 15%) from the issuer after the sale. It acts like a short-term safety valve: if demand is strong, underwriters exercise the option and supply extra shares; if the price falls, they can use the option to stabilize the market. For investors this matters because it affects how many shares come to market, potential short-term dilution, and post-offering price stability—similar to having a reserve supply to smooth out sudden swings.

prospectus supplement regulatory

"A final prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

u.s. food and drug administration (fda) regulatory

"for which there are no U.S. Food and Drug Administration (FDA)-approved therapies"

The U.S. Food and Drug Administration (FDA) is a government agency responsible for protecting public health by ensuring the safety and effectiveness of food, medicines, vaccines, and other health-related products. For investors, the FDA’s decisions can significantly impact companies in the healthcare and food industries, as approval or rejection of products can influence a company's success and stock performance.

AI-generated analysis. Not financial advice.

WAYNE, Pa., March 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it closed its previously announced upsized public offering on February 27, 2026. The offering consisted of 1,840,000 shares of its common stock, which included the exercise in full of the underwriters’ option to purchase 240,000 additional shares, at a price to the public of $125.00 per share. The aggregate gross proceeds to Palvella from this offering, before deducting underwriting discounts and commissions and offering expenses, were $230.0 million.

TD Cowen, Cantor, Stifel, Mizuho, LifeSci Capital, Oppenheimer & Co., Canaccord Genuity and H.C. Wainwright & Co. acted as joint bookrunning managers for the offering. Lucid Capital Markets, Jones, Clear Street and Craig-Hallum acted as co-managers for the offering.

Palvella intends to use the net proceeds from this offering to support the development of its programs, including QTORIN rapamycin and QTORIN pitavastatin, and for working capital and other general corporate purposes, including research and development expenses.

The shares were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-292544) that was declared effective by the Securities and Exchange Commission (“SEC”) on January 29, 2026. A final prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC and are available for free on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained, from: TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59^th Street, 6^th Floor, New York, NY 10022 or by email at prospectus@cantor.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364‐2720 or by email at syndprospectus@stifel.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

About Palvella Therapeutics

Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Palvella’s second product candidate, QTORIN™ pitavastatin, is currently being developed for the topical treatment of disseminated superficial actinic porokeratosis.

QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and neither has been approved by the FDA or by any other regulatory agency for any indication.

Caution Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend,” or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of Palvella’s management. Such forward-looking statements include, without limitation, statements relating to the use of proceeds from the public offering of common stock. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others, the risks and uncertainties set forth in the “Risk Factors” section and elsewhere in the prospectus supplement related to the public offering filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission and available at www.sec.gov, including but not limited to Palvella’s periodic reports, including Palvella’s most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and Palvella assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.

Contact Information:
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com

Media:
Marcy Nanus
Managing Partner, Trilon Advisors LLC
mmanus@trilonadvisors.com

FAQ

How many shares did Palvella (PVLA) sell in the February 27, 2026 offering?

Palvella sold 1,840,000 common shares in the offering, including the underwriters' full option of 240,000 shares. According to Palvella, the sale closed on February 27, 2026, and was conducted at $125.00 per share.

How much gross capital did Palvella (PVLA) raise from the public offering on Feb 27, 2026?

Palvella raised $230.0 million in aggregate gross proceeds from the offering. According to Palvella, this figure is before deducting underwriting discounts, commissions, and offering expenses.

What will Palvella (PVLA) use the net proceeds from the offering for?

Palvella intends to use net proceeds to advance QTORIN rapamycin and QTORIN pitavastatin development and for working capital and general corporate purposes. According to Palvella, proceeds will support research and development expenses.

Did the underwriters exercise their option in Palvella's (PVLA) offering?

Yes, the underwriters exercised their option in full, adding 240,000 shares to the offering. According to Palvella, the full exercise was included in the total 1,840,000 shares sold at $125.00 per share.

Under what registration was Palvella's (PVLA) offering conducted and when was it effective?

The offering was made pursuant to a Form S-3 shelf registration, File No. 333-292544, declared effective on January 29, 2026. According to Palvella, final prospectus documents were filed with the SEC and made available publicly.

Who managed Palvella's (PVLA) February 2026 public offering?

The offering was led by joint bookrunning managers including TD Cowen, Cantor, Stifel, Mizuho and others, with several co-managers assisting. According to Palvella, a syndicate of managers and co-managers handled the transaction.